Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vimta Labs's interest expense for the
three
months ended in Jun. 2026 was ₹ -2 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-11 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vimta Labs's Operating Income for the
three
months ended in Jun. 2026 was ₹ 248 Mil. Vimta Labs's Interest Expense for the
three
months ended in Jun. 2026 was ₹ -2 Mil.
Vimta Labs's Interest Coverage for the quarter that ended in Jun. 2026 was 104.49.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Vimta Labs Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Vimta Labs Interest Expense Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Interest Expense of ₹-11 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vimta Labs and its competitors.
Is Vimta Labs' Interest Expense too high?
Vimta Labs' current Interest Expense is ₹-11 Mil. Overall, Vimta Labs has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Interest Expense compare to TMO and DHR?
Vimta Labs' Interest Expense of ₹-11 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vimta Labs and its competitors. Vimta Labs's current Interest Expense is ₹-11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹508.27, compared to a current price of ₹632.45 — trading 24.4% above its estimated fair value. The current Interest Expense is ₹-11 Mil. Vimta Labs' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Interest Expense is ₹-11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹632.45 is trading 24.4% above its estimated GF Value™ of ₹508.27.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
Interest Expense: ₹-11 Mil
GF Value™: ₹508.27 vs. price of ₹632.45 (24.4% above fair value)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
85GF Score
Get the complete analysis for BOM:524394
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
